Advancing therapy with iGlarLixi versus premix BIAsp 30 in basal insulin-treated type 2 diabetes: Design and baseline characteristics of the SoliMix randomized controlled trial.

RJ, McCrimmon; Sifri S, Al; R, Emral; V, Mohan; L, Sauque-Reyna; C, Trescolí; N, Lalic; A, Alvarez; N, Demil; M, Coudert; A, Shaunik; M, Bonnemaire; J, Rosenstock

doi:10.1111/dom.14354

Public

Advancing therapy with iGlarLixi versus premix BIAsp 30 in basal insulin-treated type 2 diabetes: Design and baseline characteristics of the SoliMix randomized controlled trial.

Shared by NobleBlocks on Apr 29, 2021 • 12:00 AM UTC

Authors:

McCrimmon RJ

Al Sifri S

Emral R

Abstract

<h4>Aim</h4>Premix insulin is commonly used in some regions of the world, despite the higher risk of hypoglycaemia and weight gain compared with basal insulin, based on the premise that it offers a simplified insulin regimen. iGlarLixi is a once-daily titratable fixed-ratio formulation that combines...

Subject

Type 2 diabetes

Basal Insulin

Insulin Therapy

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!